A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

A. Tosco, F. de Gregorio, S. Esposito, D. de Stefano, I. Sana, E. Ferrari, A. Sepe, L. Salvadori, P. Buonpensiero, A. Di Pasqua, R. Grassia, C. A. Leone, S. Guido, G. de Rosa, S. Lusa, G. Bona, G. Stoll, M. C. Maiuri, A. Mehta, G. KroemerL. Maiuri, V. Raia

Research output: Contribution to journalArticlepeer-review

Abstract

We previously reported that the combination of two safe proteostasis regulators, cysteamine and epigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here we provide the proof-of-concept that this combination treatment restored CFTR function and reduced lung inflammation (P

Original languageEnglish
JournalCell Death and Differentiation
DOIs
Publication statusAccepted/In press - Apr 1 2016

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR'. Together they form a unique fingerprint.

Cite this